olaparib,abiraterone
merck,astrazeneca,janssen
['olaparib', 'abiraterone', 'crpc', 'propel']
tolerability of abiraterone combined with olaparib in patients with #mcrpc: further results from the phase iii #propel trial. presented by antoine thiery-vuillemin . #asco22 coverage by on urotoday &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology